New COVID-19 vaccines have been developed to target the KP.2 strain of the SARS-CoV-2 virus, reflecting the virus’s ongoing evolution. In June, the Food and Drug Administration (FDA) initially directed vaccine manufacturers to focus on the JN.1 variant. However, they later advised shifting focus to the KP.2 strain, considering the virus’s rapid changes.
The updated vaccine has been approved for individuals aged 12 and older. For children between the ages of 6 months and 4 years, the vaccine is available under emergency use authorization. The urgency of updating vaccines comes in response to the diminishing immunity seen in the population. Immunity has been waning due to both natural virus exposure and the effects of previous vaccinations wearing off. To combat this, health authorities are encouraging those eligible to receive the latest vaccine version to better guard against currently circulating variants. “Given waning immunity of the population from previous exposure to the virus and from prior vaccination, we strongly encourage those who are eligible to consider receiving an updated COVID-19 vaccine to provide better protection against currently circulating variants,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, in a statement.
The current data from the Centers for Disease Control and Prevention (CDC) shows the highest viral activity in the western United States. However, almost every state reports “high” or “very high” levels of COVID-19 virus in wastewater. This indicates a significant spread of the virus across the country. Notably, the nationwide viral levels are higher than they were at this time last year, and the increase started earlier in the summer. According to federal wastewater data, viral activity has been on the rise since mid-May, suggesting a steady upward trend in cases.
The vaccine manufacturers are preparing for rapid distribution. Moderna has announced that its updated vaccine is expected to be available in the “coming days.” Pfizer has similarly stated that it will “begin shipping immediately.” The prompt availability of these new vaccines aims to offer an additional protective layer for the American public, especially those most vulnerable to severe infections.
While a large portion of the American population has acquired some immunity through previous vaccinations, natural infections, or both, not all groups have the same level of protection. Older adults and those who are immunocompromised often cannot mount as robust an immune response and thus remain at a heightened risk for severe outcomes if infected. The new vaccines are particularly important for these groups to help mitigate that risk.
Despite the availability of vaccines, there has been a notable gap between supply and uptake. For instance, only about 20 percent of Americans received last year’s updated COVID-19 shot, highlighting a disconnect between vaccine availability and public willingness to get vaccinated. This lower-than-expected uptake poses a challenge for public health officials who are striving to increase vaccination rates, especially among high-risk groups.
In summary, as the SARS-CoV-2 virus continues to evolve, updated vaccines targeting newer strains like KP.2 are crucial for maintaining public health. Health officials emphasize the importance of these vaccines, especially for older and immunocompromised individuals who are at higher risk. With vaccines becoming available soon, there is a renewed push to encourage eligible individuals to get vaccinated to protect themselves and others from the ongoing threat of COVID-19.
